NYSE:NUVB

Nuvation Bio Competitors

$10.00
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.00
Now: $10.00
$10.02
50-Day Range
$9.83
MA: $11.53
$14.57
52-Week Range
$8.56
Now: $10.00
$15.07
Volume33,770 shs
Average Volume827,626 shs
Market Capitalization$2.18 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Nuvation Bio (NYSE:NUVB) Vs. ABCL, SANA, ABCM, SEER, IBRX, and BCAB

Should you be buying NUVB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Nuvation Bio, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), ImmunityBio (IBRX), and BioAtla (BCAB).

Nuvation Bio (NYSE:NUVB) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Nuvation Bio and AbCellera Biologics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
AbCellera BiologicsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nuvation Bio and AbCellera Biologics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
AbCellera Biologics00503.00

Nuvation Bio currently has a consensus target price of $17.40, indicating a potential upside of 74.00%. AbCellera Biologics has a consensus target price of $52.80, indicating a potential upside of 89.11%. Given AbCellera Biologics' higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Nuvation Bio.

Profitability

This table compares Nuvation Bio and AbCellera Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
AbCellera BiologicsN/AN/AN/A

Nuvation Bio (NYSE:NUVB) and Sana Biotechnology (NASDAQ:SANA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Nuvation Bio and Sana Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nuvation Bio and Sana Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Sana Biotechnology02202.50

Nuvation Bio currently has a consensus target price of $17.40, indicating a potential upside of 74.00%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 51.46%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Sana Biotechnology.

Profitability

This table compares Nuvation Bio and Sana Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Sana BiotechnologyN/AN/AN/A

Summary

Nuvation Bio beats Sana Biotechnology on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Nuvation Bio and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
AbcamN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nuvation Bio and Abcam, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Abcam04302.43

Nuvation Bio currently has a consensus target price of $17.40, indicating a potential upside of 74.00%. Abcam has a consensus target price of $22.00, indicating a potential upside of 13.23%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Abcam.

Valuation and Earnings

This table compares Nuvation Bio and Abcam's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Abcam on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Nuvation Bio00603.00

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.98%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Seer.

Profitability

This table compares Seer and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Nuvation BioN/AN/AN/A

Valuation & Earnings

This table compares Seer and Nuvation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Nuvation Bio and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
ImmunityBio00103.00

Nuvation Bio currently has a consensus price target of $17.40, indicating a potential upside of 74.00%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 55.38%. Given Nuvation Bio's higher probable upside, equities research analysts plainly believe Nuvation Bio is more favorable than ImmunityBio.

Profitability

This table compares Nuvation Bio and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
ImmunityBioN/AN/AN/A

Valuation and Earnings

This table compares Nuvation Bio and ImmunityBio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and BioAtla (NASDAQ:BCAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Nuvation Bio and BioAtla, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
BioAtla00403.00

Nuvation Bio currently has a consensus price target of $17.40, indicating a potential upside of 74.00%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 20.26%. Given Nuvation Bio's higher probable upside, equities research analysts plainly believe Nuvation Bio is more favorable than BioAtla.

Profitability

This table compares Nuvation Bio and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
BioAtlaN/AN/AN/A

Valuation and Earnings

This table compares Nuvation Bio and BioAtla's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats BioAtla on 2 of the 2 factors compared between the two stocks.


Nuvation Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$27.92flat$7.52 billionN/A0.00Increase in Short Interest
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$26.41flat$4.95 billionN/A0.00
Abcam logo
ABCM
Abcam
1.5$19.43flat$4.41 billionN/A0.00News Coverage
Gap Up
SEER
Seer
1.2$53.55flat$3.26 billionN/A0.00Increase in Short Interest
IBRX
ImmunityBio
1.7$16.09flat$1.76 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$48.23flat$1.62 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$32.22flat$1.39 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$28.61flat$1.36 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$29.99flat$1.30 billionN/A0.00Increase in Short Interest
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$29.87flat$1.30 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$35.15flat$1.23 billionN/A0.00
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.13flat$1.19 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.63flat$1.18 billionN/A0.00Increase in Short Interest
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.05flat$951.68 millionN/A0.00Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.01flat$923.52 millionN/A0.00News Coverage
FDMT
4D Molecular Therapeutics
1.3$34.42flat$918.81 millionN/A0.00Increase in Short Interest
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.89flat$910.67 millionN/A0.00Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.27flat$851.85 millionN/A0.00Increase in Short Interest
PHAR
Pharming Group
0.0$12.80flat$816.72 millionN/A0.00Decrease in Short Interest
Gap Up
FNCH
Finch Therapeutics Group
0.3$17.10flat$806.18 millionN/A0.00News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$21.84flat$793.40 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.35flat$554.34 millionN/A0.00News Coverage
SGTX
Sigilon Therapeutics
1.4$17.43flat$548.92 millionN/A0.00Increase in Short Interest
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$12.59flat$541.36 millionN/A0.00Analyst Revision
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.74flat$445.72 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.50flat$443.53 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.81flat$436.66 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.74flat$426.49 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.15flat$407.20 millionN/A0.00
PRTG
Portage Biotech
0.0$28.97flat$350.05 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.60flat$306.31 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.99flat$296.84 millionN/A-2.76
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.53flat$262.22 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$12.31flat$235.36 millionN/A0.00Increase in Short Interest
Gap Down
LBPH
Longboard Pharmaceuticals
1.9$12.99flat$219.75 millionN/A0.00
Annovis Bio logo
ANVS
Annovis Bio
0.0$25.07flat$174.16 millionN/A0.00
GANX
Gain Therapeutics
1.0$14.00flat$158.63 millionN/A0.00Analyst Report
News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$18.62flat$152.78 millionN/A0.00
LGVN
Longeveron
0.3$6.92flat$129.45 millionN/A0.00News Coverage
EVAX
Evaxion Biotech A/S
1.7$6.40flat$122.87 millionN/A0.00Gap Down
UPC
Universe Pharmaceuticals
0.0$4.22flat$91.79 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.73flat$61.47 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.56flat$55.88 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.99flat$49.90 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.72flat$43.82 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.44flat$30.24 millionN/A0.00High Trading Volume
VRPX
Virpax Pharmaceuticals
0.3$4.78flat$23.64 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$39.73flat$18.44 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.71flat$15.16 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.92flat$3.03 millionN/A0.00High Trading Volume
News Coverage
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.